-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The distribution and prognostic role of HER2 in colorectal cancer
Distribution and prognostic role of HER2 in colorectal cancerMetastatic colorectal cancer (mCRC) has a poor prognosis, with a 5-year survival rate of less than 20%, and is the second most common cause of cancer death worldwi.
Breast cancer and gastric cancer 10% to 15%
HER2 is a transmembrane receptor in the epidermal growth factor receptor (EGFR) fami.
HER2 amplification occurs in 5% of patients with RAS/BRAF wild-type mCRC and has also been reported in patients with KRAS tumor mutatio.
Although retrospective studies have shown that HER2 amplification is associated with resistance to anti-EGFR therapy, HER2 status has little effect on the prognosis of mCRC patients [1]
[1] Guide
Since HER2 has been recognized as a therapeutic target for mCRC patients, there are currently standardized criteria for detecting HER2 amplification by immunohistochemistry (IHC) or in situ hybridization (ISH.
Immunity [2]
HER2-targeted therapy has strong potential
HER2-targeted therapy has strong potentialMany single-arm phase 2 studies of trastuzumab combination therapy have demonstrated that HER2 amplification is a true molecular target in patients with mCRC [3-7]
[3-7] [3] [4] [5]
The 2020 edition of the CSCO colorectal cancer diagnosis and treatment guidelines [8] added the recommendation of anti-HER2 therapy for the first time in the third-line or later-line treatment of colorectal canc.
diagnosis and treatment [8]
Summarize
SummarizeColorectal cancer is one of the important tumor diseases that affects the health of Chinese residen.
precise
references:
references:Yonesaka K, Zejnullahu K, Okamoto I, et .
Yonesaka K, Zejnullahu K, Okamoto I, et .
Valtorta E, Martino C, Sartore-Bianchi A, et .
Tosi F, Sartore-Bianchi A, Lonardi S, et .
Strickler JH, Zemla T, Ou FS, et .
Meric-Bernstam F, Hurwitz H, Raghav KPS, et .
Gupta R, Garrett-Mayer E, Halabi S, et .
Nakamura Y, Okamoto W, Kato T, et .
Chinese Society of Clinical Oncology (CSCO) Colorectal Cancer Diagnosis and Treatment Guidelines 202Leave a message here
